Wearables Meet GLP-1: A New Focus on Muscle Loss
Samsung’s new Galaxy Watch 8 study is a research initiative that uses wearable health monitoring to track GLP-1 muscle loss and other metabolic changes in people starting weight-loss and diabetes medications, with the goal of building personalized health plans that preserve strength while supporting safe, sustainable weight reduction. The company is partnering with the Diabetes Research Centre at Massachusetts General Hospital to monitor adults prescribed GLP-1 receptor agonists such as Ozempic and similar drugs. Using Galaxy Watch health tracking and the Samsung Health platform, researchers will follow body composition, heart rate, and physical activity as participants begin treatment. Interest in GLP-1 muscle loss has surged as these drugs expand beyond diabetes into weight management. According to health policy organization KFF, almost one in five adults in the United States has used a GLP-1 drug at some stage, raising questions about long-term effects that wearables may help clarify.
Inside the Study: How Galaxy Watch 8 Tracks Muscle and Movement
The clinical trial will enroll 100 adults who are at the start of GLP-1-induced weight-loss treatment and split them into two groups. One group will wear the Galaxy Watch 8, which uses Bioelectrical Impedance Analysis to estimate body composition and combines this with continuous activity and heart-rate data. These users receive personalized exercise guidance designed to counter GLP-1 muscle loss while they lose weight. The control group follows standard advice given to GLP-1 patients without smartwatch-guided insights. Researchers will compare watch data with clinical-grade DXA scans to see how well wearable health monitoring can track lean mass over time. Samsung describes the study as a test of whether continuous Galaxy Watch health tracking can give clinicians a more complete view of treatment, enabling earlier, data-driven adjustments to reduce muscle wasting and other drug side effects.
Why GLP-1 Muscle Loss Matters for Long-Term Health
GLP-1 medications are effective at lowering blood sugar and driving weight loss, partly by reducing appetite, but that benefit comes with a trade-off: rapid loss of lean tissue. Dr David N. Brennan of the Mayo Clinic notes that more than 30% of the weight lost on GLP-1 drugs may come from muscle. Researchers from the University of Virginia have highlighted that axial muscle, which stabilizes posture and supports movement, is vital for daily function and cardiovascular health. Losing this mass can weaken strength, impair mobility, and raise the risk of cardiovascular disease, especially in older adults or those already prone to frailty. Dr Melissa Putman from Massachusetts General Hospital warns that GLP-1 muscle loss can also lower basal metabolic rate, making future weight regain more likely. These concerns are driving demand for tools that track not only pounds lost but the quality of that weight loss.
From Step Counters to Drug Side Effects Monitoring
The Galaxy Watch 8 study marks a shift in wearables from counting steps to drug side effects monitoring. Instead of focusing only on calories burned or daily activity rings, the watch is being used as a real-time sensor for how a specific class of medications affects body composition and metabolism. Continuous wearable health monitoring means clinicians can see trends in GLP-1 muscle loss, resting heart rate, and activity patterns between clinic visits. According to Samsung, combining these metrics with standard care could give doctors a more holistic picture of each patient’s treatment journey. The trial’s control design, where one group receives smartwatch-driven coaching and the other follows usual advice, will test whether targeted interventions delivered on the wrist can help preserve muscle and protect long-term health while patients pursue GLP-1-driven weight loss.
Personalized Health Plans and the Future of Preventive Monitoring
If the study succeeds, it could redefine how people use wearables alongside weight-loss medications. Galaxy Watch health tracking may become a foundation for personalized health plans that respond to early warning signs of GLP-1 muscle loss, nudging users toward specific strength exercises, higher activity targets, or nutrition adjustments. Dr Melissa Putman notes that continuous data on activity, heart rate, and body composition can give clinicians “a more holistic view of treatment impact” and support timely changes to care plans. Samsung’s collaboration with Massachusetts General Hospital continues a broader trend of tech companies expanding wearable health monitoring into preventive care and long-term condition management. Rather than waiting for complications, devices like Galaxy Watch 8 could help users and clinicians act earlier, making pharmaceutical weight loss safer by keeping an eye on the hidden costs of rapid change.